1[1]Alderman MH.Uric acid and cardiovascular risk[J].Cuur Opin Pharmacol,2002,12:126-129.
2[5]Verdecchia P,Schillaci G,Reboldi G,et al.Relation between serum uric acid and risk of cardiovascular disease in essential hypertension.The PIUMA Study[J].Hypertension,2000,36:1072-1078.
3Bauer JH, Reams GP. The angiotensin Ⅱ Type Ⅰ receptor antagonists. A new class of antihypertensive drugs [J]. Arch Intern Med, 1995, 155:1361-1368.
6Coreal, Cardoni V, Fogari R, et al. Valsartan, a new angiotensin Ⅱ antagonist for the treatment of essential hypertension: Acomparative study of the efficay and safety against amlodipine[J], Clin Pharmacol Ther, 1996, 60:341-346.
7Chiu AT, Mccall DE, Price WA, et al. In vitro pharmacology of dup 753 [J]. Am J Hypertens, 1991, 4:5282.
8Pecers H, Border WA, Noble NA, et al. Targeting TGF-β1 overexpression in renal disease: maximizing the antifibrotic action of angiotensin Ⅱ blockade [J]. Kidney Int, 1998, 1570-1580.
9Geiger H,Fierlbeck W,Mai M,et al. Effect of early and are antihypertenaive treatment on extracellular matrix proteira and mononuclear cells in uninephrectonized SHR [J]. Kidney Int, 1997, 51 (3):750-761.
